Skip to main content

Rewiring with biased signaling to override oxidative pathway defects for SEPN1-related myopathy therapy

Project description

Rewiring signalling to find therapy for SEPN1-related myopathy

Selenoprotein-related myopathy (SEPN1-RM) is a rare untreatable congenital myopathy in which SEPN1 mutations impair the antioxidant system and mitochondrial oxidative function, leading to a significant loss of bioenergetic production and muscle cell functions, potentially lethal respiratory failure and mobility impairment. The EU-funded REBOOST project aims to use patient-derived cells to establish high-throughput readouts of metabolism, facilitating drug repurposing for SEPN1-RM, and employ original treatment strategies exploiting signallings bypassing SEPN1 defects to restore cellular bioenergetics. This study will facilitate the establishment of SEPN1-RM biomarkers and novel therapeutic studies, and provide a model approach for the analysis and treatment of other inherited or acquired myopathies sharing an underlying bioenergetic deficiency, including sarcopenia and cancer cachexia.

Call for proposal

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries


85 Bd Saint Germain
75006 Paris
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 196 707,84